Targeting FLT3 mutations in AML: review of current knowledge and evidence
The University of Texas MD Anderson Cancer Center · German Cancer Research Center · +5 more institutions
Abstract
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, and new therapeutic targets. Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approximately 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation (FLT3-ITD; approximately 25% of all AML cases). FLT3-ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML. The prognostic value of a FLT3 mutation in the tyrosine kinase domain (FLT3-TKD), which has a lower incidence in AML (approximately 7-10%…
Citation impact
- FWCI
- 88.54
- Percentile
- 100%
- References
- 101
Authors
4- NDNaval Daver
The University of Texas MD Anderson Cancer Center
- RFRichard F. Schlenk
German Cancer Research Center, Heidelberg University, National Center for Tumor Diseases
- NHNigel H. Russell
Nottingham University Hospitals NHS Trust
- MJMark J. LevisCorresponding
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Topics & keywords
- Fms-Like Tyrosine Kinase 3
- Myeloid leukemia
- Medicine
- Mutation
- Tyrosine kinase
- Targeted therapy
- Disease
- Cancer research